Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy

Alison Halliday*, Richard Bulbulia*, Leo H Bonati, Johanna Chester, Andrea Cradduck-Bamford, Richard Peto†, Hongchao Pan†, for the ACST-2 Collaborative Group‡

Summary

Background Among asymptomatic patients with severe carotid artery stenosis but no recent stroke or transient cerebral ischaemia, either carotid artery stenting (CAS) or carotid endarterectomy (CEA) can restore patency and reduce long-term stroke risks. However, from recent national registry data, each option causes about 1% procedural risk of disabling stroke or death. Comparison of their long-term protective effects requires large-scale randomised evidence.

Methods ACST-2 is an international multicentre randomised trial of CAS versus CEA among asymptomatic patients with severe stenosis thought to require intervention, interpreted with all other relevant trials. Patients were eligible if they had severe unilateral or bilateral carotid artery stenosis and both doctor and patient agreed that a carotid procedure should be undertaken, but they were substantially uncertain which one to choose. Patients were randomly allocated to CAS or CEA and followed up at 1 month and then annually, for a mean 5 years. Procedural events were those within 30 days of the intervention. Intention-to-treat analyses are provided. Analyses including procedural hazards use tabular methods. Analyses and meta-analyses of non-procedural strokes use Kaplan-Meier and log-rank methods. The trial is registered with the ISRCTN registry, ISRCTN21144362.

Findings Between Jan 15, 2008, and Dec 31, 2020, 3625 patients in 130 centres were randomly allocated, 1811 to CAS and 1814 to CEA, with good compliance, good medical therapy and a mean 5 years of follow-up. Overall, 1% had disabling stroke or death procedurally (15 allocated to CAS and 18 to CEA) and 2% had non-disabling procedural stroke (48 allocated to CAS and 29 to CEA). Kaplan-Meier estimates of 5-year non-procedural stroke were 2.5% in each group for fatal or disabling stroke, and 5.3% with CAS versus 4.5% with CEA for any stroke (rate ratio [RR] 1.16, 95% CI 0.86–1.57; p=0.33). Combining RRs for any non-procedural stroke in all CAS versus CEA trials, the RR was similar in symptomatic and asymptomatic patients (overall RR 1.11, 95% CI 0.91–1.32; p=0.21).

Interpretation Serious complications are similarly uncommon after competent CAS and CEA, and the long-term effects of these two carotid artery procedures on fatal or disabling stroke are comparable.

Funding UK Medical Research Council and Health Technology Assessment Programme.

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction

Severely stenosed carotid arteries predispose to stroke, and either carotid artery stenting (CAS) or carotid endarterectomy (CEA) can restore patency and reduce the long-term risk of stroke. Open carotid artery surgery completely removes the atheromatous material, but stenting is less invasive. In North America, some 100 000 surgery or stenting procedures are done each year to treat carotid artery narrowing, and numbers are similar for Europe. About half are to prevent recurrent stroke in symptomatic patients and half are for primary stroke prevention in asymptomatic patients (ie, those whose stenosis has not caused any recent ipsilateral symptoms), but this proportion varies from one country to another. Among asymptomatic patients with severe (eg, 70–99%) stenosis, successful CEA approximately halves the long-term stroke risk. Both CAS and CEA, however, carry a short-term risk of stroke, which is about twice as great for symptomatic as for asymptomatic patients. When carotid procedures first became common, these risks were substantial, but nowadays they are much lower, particularly among asymptomatic patients. In Germany, for example, where all carotid procedures must, by law, be registered, during 2014–19, the in-hospital risk of disabling stroke or death among asymptomatic patients undergoing CAS (n=18 000) or CEA (n=86 000) was 0.7% for each procedure (appendix p 9); the additional in-hospital risk of non-disabling stroke was 1.1% for CAS and 0.7% for CEA. These rates are below the conventional 3% safety threshold, although only about two thirds of procedural strokes occur before hospital discharge. In this large German registry, the in-hospital risk of stroke after a carotid procedure was reliably shown to be unrelated to...
Evidence before this study
In patients with severe carotid artery stenosis, carotid artery stenting (CAS) and carotid endarterectomy (CEA) both carry procedural risks, which are about twice as great for symptomatic as for asymptomatic patients, but they can restore patency and approximately halve long-term stroke rates in asymptomatic patients. The procedural risks have decreased over the decades, but there is still a about 1% risk of disabling stroke or death. There is also some procedural risk of non-disabling stroke (particularly with CAS) or of non-fatal myocardial infarction or cranial nerve palsy (particularly with CEA). Modern drug therapy can also reduce stroke rates but even with it, patients with severe carotid stenosis might have a risk of about 1% per year of disabling stroke or death. Hence, in addition to good medical therapy, carotid procedures are still considered appropriate for many patients. However, there is often uncertainty as to whether CAS or CEA would be more appropriate. Previous trials, first among symptomatic and then among asymptomatic patients, have directly compared CAS versus CEA. Particularly for asymptomatic patients, however, the numbers randomised have been limited, as shown by the 2020 Cochrane review led by LHB (which defines the search strategy for such trials in the present report). The aim of this study was to randomly assign substantial numbers of asymptomatic patients, and then to consider the results in the context of those from all other trials of CAS versus CEA.

Methods
Study design and participants
ACST-2 is an international multicentre randomised trial done in 33 countries (appendix pp 3–8). Asymptomatic patients with carotid artery stenosis who were thought suitable for CAS or for CEA could enter ACST-2 if the doctor and patient were both substantially uncertain which procedure to prefer. All other aspects of the management of patients were left to the discretion of the clinician and usually included antithrombotic, antihypertensive, and lipid-lowering therapy. The trial compared the 30-day hazards of the two procedures when done by experienced doctors and the subsequent stroke rates over the following 5–10 years. The original trial protocol is provided in the appendix (pp 19–46). 130 hospitals collaborated, each with a vascular surgeon, an interventionalist (perhaps the same person), and a neurologist (or stroke doctor). Potential collaborators submitted a record of their CAS or CEA experience and procedural outcomes. These were anonymised and reviewed; for participation, the risks of any stroke or death had to be 6% or lower for symptomatic patients and 3% or lower for asymptomatic patients. Ethics approval was obtained at each centre and at the UK coordinating centre. Written informed consent was given before randomisation. Interim analyses were supplied annually to the Data Monitoring Committee but never justified disclosure.

Added value of this study
ACST-2 has randomly allocated 3625 asymptomatic patients with severe carotid stenosis to CAS or CEA with good compliance and, thus far, a mean of 5 years of follow-up. The procedures themselves each involved a 1% risk of causing disabling stroke or death but, after each of them, the annual rate of disabling or fatal stroke was only about 0.5%. This study has more than doubled the number of asymptomatic patients in trials of CAS versus CEA. However, the randomised evidence from both asymptomatic and symptomatic patients is relevant to any comparison between the two procedures. With ACST-2 included, there is now as much evidence among asymptomatic as among symptomatic patients, and the findings in both types of patient are remarkably similar, with CAS about as effective as CEA at reducing the annual risk of stroke, at least for the first few years.

Implications of all the available evidence
The trials of CAS versus CEA now provide better evidence than existed before that both procedures carry similar risks and provide comparable benefits. This does not address the question of whether, in addition to good medical therapy, a skilful carotid intervention would be appropriate, nor does it address the question of how much each procedure costs to health services or patients. It does, however, mean that doctors and patients have a freer choice of which procedure is more appropriate for individuals.
patients, plaque echolucency was also estimated. No images were collected centrally.

Patients were eligible if they had severe unilateral or bilateral carotid artery stenosis (generally 60% or higher on ultrasound); this had not caused any relevant neurological symptoms in the preceding 6 months; there was CT or MRI confirmation of suitability for CAS and for CEA (which would also have been used to exclude from trial entry any patient without sufficient stenosis to justify intervention); the doctor and patient agreed that a carotid procedure should be undertaken, but they were substantially uncertain whether this should be CAS or CEA; and the patient had no known circumstance or condition likely to preclude long-term follow-up.

Exclusion criteria included previous ipsilateral intervention, unsuitability for CAS (eg, due to calcification or tortuosity) or CEA, high procedural risk (eg, because of recent acute myocardial infarction), high risk of cardiac emboli, or any major life-threatening condition. Patients likely to require other surgery could not enter the trial until at least 1 month after it.

Randomisation
Informed consent was obtained before randomisation. Electronic entry through the Oxford Clinical Trial Service Unit recorded patient characteristics before a computer generated the 1:1 random allocation to ipsilateral CAS or CEA. The allocation was minimised on patient characteristics but, to avoid local foreknowledge, not on centre. Anonymised clinical records were reviewed by the Endpoint Committee, after masking any information indicating the allocated or actual treatment. Masking was complete for non-procedural events, but for procedural events (ie, those occurring before 30 days after the intervention) it was sometimes not possible.

Procedures
Collaborators used their normal procedures. For CAS, any CE-approved devices were allowed, and procedural double antiplatelet therapy was usual. For CEA, shunting and patching were optional. Long-term medical care was to be similar in both groups and generally involved antithrombotic, antihypertensive, and lipid-lowering therapy.

No tests for silent myocardial infarction were required. Patients were assessed neurologically after their procedure by the collaborating neurologist or stroke doctor, either while still in hospital or within 30 days. Follow-up reports were at 1 month after treatment (including procedural morbidity and duplex ultrasound), and yearly after randomisation (reporting on drug treatment, any later carotid procedures, and any strokes or deaths). Follow-up is continuing (for up to 12 years, thus far). UK death certificates were sent automatically to the trial office; elsewhere, mortality follow-up was through collaborating hospitals or the annual enquiries to patients or carers. If probable strokes were reported,
Figure 1: Trial profile
CAS=carotid artery stenting. CEA=carotid endarterectomy.

Table 1

| CAS Procedures | CEA Procedures |
|----------------|----------------|
| 178 ipsilateral CAS within 1 year (median 14 days, IQR 4-33) | 3 ipsilateral CEA later |
| 21 contralateral CAS | 14 contralateral CEA |
| 101 ipsilateral CEA (ie, crossover) | 48 ipsilateral CAS (ie, crossover) |
| 2 contralateral CEA | 3 contralateral CAS |
| 106 never had any carotid procedure | 78 never had any carotid procedure |

Outcomes and endpoint classification

The main trial outcomes were procedural mortality and morbidity (ie, onset before 30 days after the intervention) and, most importantly, non-procedural stroke, subdivided by severity. Strokes had to involve symptoms lasting more than 24 h; any imaging was used to help define the nature of the stroke. Confirmed strokes were classified by site, nature, and eventual outcome after 6 months: non-disabling (modified Rankin Scale [mRS] score 0–2, which involves at most slight residual disability because of the stroke, with patients still able to walk and look after their own affairs without assistance), disabling (mRS score 3–5, which involves at least moderate disability from the stroke, with patients requiring help), or fatal (causing death in any direct or indirect way, regardless of the time between stroke onset and death). The mRS scores are defined more fully in the study protocol (appendix p 26). If the patient died of another cause within 6 months of stroke onset, an estimate of stroke severity was made. A fatal stroke was one that caused death, either directly or indirectly, regardless of the delay between stroke and death; thus, procedural strokes could take more than 30 days to prove fatal. Confirmation of a myocardial infarction required at least two of three criteria: symptoms, biomarker elevation, or electrocardiogram changes.

Statistical analysis

The original intent was to randomly assign 1000 patients per year for 5 years between CAS and CEA, then follow up all for 5 years after the last patient entered. To facilitate rapid recruitment, entry procedures were simplified and the consent form had a simple front and back page (with details elsewhere only for those wanting them). If, however, prospective participants had already been referred for stenting or for CEA, eligibility for randomisation required consideration of an alternative procedure. Hence, only about 300 patients per year were randomly assigned between CAS and CEA and, after 5 years, investigators were invited to continue randomising, aiming for a reduced target of 3600. The protocol was not modified, as collaboration with other trials was arranged that would yield in total more than 5000 patients by 2020.

The only written statistical analysis plan was that in the protocol (appendix pp 19–46), where the stated primary objectives were to compare the effects of CAS and CEA on procedural risks and on “long-term (up to 5 or more years) prevention of stroke, particularly disabling or fatal stroke”. The sample size considerations imply that the results from ACST-2 should be analysed not in isolation but in conjunction with those from other trials. Analyses in the Discussion include all trials of CAS versus CEA found by the literature-searching strategy of the 2020 Cochrane review (which was led by LH B).

Procedural hazards in nationally representative large registries are now available. Hence, the most important trial results are those on non-procedural strokes. When combining such results from several trials, inverse-variance-weighted averages of the log of the rate ratio (RR) in each trial were used, with 95% CIs for the overall result and 99% confidence limits for each separate trial result. All p values are two-sided.

Analyses of procedural risks related to the first intervention after randomisation, and the intention-to-treat (ITT) analyses were complemented by analyses of procedural risks in those who actually underwent CAS or CEA. The main analyses of non-procedural stroke rates involved log-rank methods. Follow-up was to death or last report of being alive.

ITT analyses and Kaplan-Meier time-to-first-event graphs are provided for all outcomes. Standard continuity-corrected methods for 2×2 tables are used for p value calculation for any outcomes that include procedural hazards. Proportional hazards methods (log-rank tests, stratified by age [younger than 65 years, 65–74 years, and 75 years or older] and sex into six groups) are used for p value calculation for non-procedural stroke RR.s.

For non-procedural stroke rates, the log of the event RR is estimated from the log-rank observed minus expected (O–E) and its variance V as (O–E)/V, taken to be normally distributed with variance 1/V. This leads to χ² tests of interaction between various baseline features and the effects of treatment allocation on non-procedural stroke rates. Summation of these χ² tests (and, separately, of their degrees of freedom)
leads to an approximate global $\chi^2$ test of the relevance of any of these features to the trial treatment comparison.

Proportional-hazard methods are not used for analyses that combine procedural hazards with long-term stroke rates. For early risk from an intervention may be followed by later benefit, so the hazard ratio comparing one treatment versus another could well go first in one direction then in another (invalidating methods that assume approximately constant hazard ratios). Analyses used SAS, version 9.4, and R, version 4.1. The trial is registered with the ISRCTN registry, ISRCTN21144362.

Role of the funding source
The study sponsors had no role in design, data collection, analysis, interpretation, or report writing.

Results
3625 patients from 130 centres in 33 countries were randomly allocated between Jan 15, 2008, and Dec 31, 2020, 1811 to CAS and 1814 to CEA. As minimised randomisation was used, patient characteristics did not differ (table 1). Figure 1 shows treatment allocated and actually received. Compliance was good, and treatment was prompt (appendix p 10). Among those allocated to CAS, 1578 (87%) had it within 1 year, at median 14 days (IQR 4–33) after randomisation, 101 (6%) crossed over to CEA, and 106 (6%) had no intervention. Among those allocated CEA, 1668 (92%) had it within a year, again at median 14 days (IQR 4–33) after randomisation, 48 (3%) crossed over to CAS, and 106 (6%) had no intervention. Reasons for crossing over from CAS to CEA included finding that the stenosis was highly calcified or that the carotid artery was more tortuous than anticipated. Reasons for crossing over from CEA to CAS included the patient’s or doctor’s preference, or reluctance to undergo general anaesthesia. Only about half the CAS procedures were done by a radiologist; most of the others were done by vascular surgeons. The techniques and drug treatment of those having CAS and CEA as their first carotid procedure after randomisation is described in the appendix (pp 11–14); CAS was usually accompanied by double antiplatelet therapy.

Table 2 describes the procedural hazards in those who had an intervention, subdivided both by the first intervention actually undertaken and by the random allocation; in both analyses, the findings were similar. Among those who actually had CAS or actually had CEA, there was a small excess of non-disabling strokes after CAS (45 vs 32, including 15 vs 6 with no residual symptoms at all [mRS score 0]) and a small excess of myocardial infarction after CEA (four vs 13), but the overall risk of death or disabling stroke was similar: CAS 1·0% (17 of 1653) versus CEA 0·9% (15 of 1788). The risk of stroke within 30 days was similar between CAS done by radiologists and other operators (appendix p 15). Nine procedural strokes were haemorrhagic (six CAS vs three CEA, including one vs one disabling). For patients without complications, mean hospital stay was 1 day shorter after CAS than after CEA (4·2 days, SD 9·0, vs 5·4 days, SD 10·1); about two thirds of the procedural events occurred before these medians

| Had no carotid procedure | Allocated CAS (n=1811) | Allocated CEA (n=1814) | p value Had CAS first | Had CEA first |
|-------------------------|------------------------|------------------------|----------------------|--------------|
| Had a carotid procedure† | 1705                   | 1736                   | 0·77                 | 6            |
| Worst procedural stroke, mRS score | 6 (fatal) | 5   | 0·07 | 6  | 6 |
|                        | 3–5 (disabling)        | 6   | 1·00 | 8  | 5 |
|                        | 2                      | 9   | 1·00 | 9  | 9 |
|                        | 1                      | 23  | 0·25 | 21 | 17 |
|                        | 0                      | 16  | 0·03 | 15 | 6 |
| 0–2 (non-disabling)    | 48 (2·7%)              | 29 (1·6%)              | 0·03                 | 45 (2·7%)    |
| Subtotal: any stroke   | 61 (3·6%)              | 41 (2·4%)              | 0·06                 | 59 (3·6%)    |
| Death or any MI        | 0                      | 4               | 0·13            | 0  | 4 |
| MI                      | 2                      | 1               | 0·13            | 2  | 1 |
| Other death            | 6                      | 7               | 1·00            | 6  | 7 |
| Death, MI or any stroke| 67 (3·9%)              | 55 (3·2%)              | 0·26                 | 65 (3·9%)   |
| Death or any stroke     | 63 (3·7%)              | 47 (2·7%)              | 0·12                 | 62 (3·8%)   |
| Death or disabling stroke| 15 (0·9%)              | 18 (1·0%)              | 0·77                 | 17 (1·0%)   |
| Subtotal: any non-procedural stroke | 91 (5·2%) | 79 (4·5%) | 0·15 |

Data are n or n (%), unless otherwise specified. CAS=carotid artery surgery. CEA=carotid endarterectomy. MI=myocardial infarction. mRS=modified Rankin Scale. ²First carotid procedure undergone after randomisation. ¹Denominator for percentages. One groin haemorrhage after CAS, one unrelated trauma death after CAS, one cervical haemorrhage after CEA, and one generalised sepsis (allocated CEA but got CAS).

Table 3: Non-procedural strokes during follow-up

| Procedural stroke or death* | 63 | 47 |
|----------------------------|----|----|
| No procedural stroke or death* | 12/48 | 176/ |
Only non-procedural strokes. The upper two panels include procedural events, and the right panels show treatment (intention-to-treat analyses). The left panels versus all those allocated CEA, regardless of their actual 5-year outcome, comparing all those allocated CAS versus everything allocated CEA. Among those who had a carotid procedure no material differences in usage between those allocated CAS and CEA. Among those who had a carotid procedure CAS did not cause cranial nerve palsy. Table 1 describes the 1-month form (33 n.XII, 29 n.VII, 23 n.X, six n.V, three n.XI, one n.VIII, and one n.IX). deviation was 3·1 (range 0–12; figure 1). Annual follow-up is still continuing, with wide use of antithrombotic, antihypertensive, and lipid-lowering therapy (appendix p 17) and continuing, with wide use of antithrombotic, antihyper...
procedural and other deaths, the random allocation to CAS or CEA had no significant effect on overall stroke mortality (23 CAS vs 25 CEA stroke deaths; RR 0.93, 95% CI 0.53–1.63; p=0.80; tables 2, 3) or on all-cause mortality (330 vs 313 deaths, 92% of which were not from stroke; 1.04, 0.89–1.21; p=0.63).

Discussion

This trial does not address the question of whether, or when, a carotid intervention would be appropriate, as it was restricted to patients in whom intervention was considered necessary, and all participants were to receive CAS or CEA. Previous trials of CEA versus no carotid procedure in asymptomatic patients had, however, already shown that CEA approximately halves the subsequent incidence of disabling or fatal stroke. They had also shown that this approximate halving of non-procedural stroke rates by CEA did not depend significantly on age, sex, or use of effective medical treatment (which also reduces stroke rates substantially).

The main finding from the ACST-2 trial of CAS versus CEA is that the effects of the two procedures on disabling or fatal events are approximately equal in terms of procedural hazards (about 1% for each treatment, in line with findings from large, representative registries) and of 5-year disabling stroke rates (which were about 0–5% per year with either procedure, suggesting that they would have been about 1% per year with neither procedure). Non-disabling procedural stroke rates appeared to be slightly higher with CAS, again consistent with recent results from registries. The chief limitation of ACST-2 is the study size; this is the largest carotid intervention trial yet conducted, but still it must be considered together with all other trials of CAS versus CEA.
Patients and doctors who take part in trials may well be atypical in various ways, so the absolute procedural hazards for typical patients treated by typical doctors may be better assessed by considering thoughtfully the evidence from large, recent, representative registries or routine health-care databases rather than by considering just the evidence from randomised trials. In the national German registry, asymptomatic patients undergoing CAS or CEA during 2014–19 had in both cases an in-hospital risk of disabling stroke or death of 0·7%, with median time to discharge of 4–5 days15 (appendix p 9). A risk of 0·7% within 4–5 days suggests a 30-day risk of disabling stroke or death of about 1% for each procedure, which is similar to that in ACST-2. Both in the German registry data and in ACST-2, CAS was associated with a slightly greater risk than CEA of non-disabling stroke.

Treatment was equally prompt in both study arms, so procedural endpoints could be defined as those within 30 days of the procedure (rather than within a fixed time since randomisation, as in some previous trials). The chief emphasis was on stroke, particularly disabling stroke, as procedural myocardial infarction was much less common than expected in the protocol, but there was no evidence that myocardial infarction had been underestimated. Cranial nerve damage following CEA was monitored only at 1 month, as it is usually either underestimated. Cranial nerve damage following CEA was no evidence that myocardial infarction had been less common than expected in the protocol, but there may be systematic differences between the types of patients who undergo CAS and CEA that cannot be sufficiently controlled by mathematical modelling or propensity matching. Large-scale randomised evidence is necessary,4 and the present trial has more than doubled the number of asymptomatic patients in trials of CAS versus CEA.12–14 However, the randomised evidence from both asymptomatic and symptomatic patients is relevant.14–18 This is summarised in figure 4, the main aim of which is to see whether the results among the two types of patient can help reinforce each other, rather than to seek differences between them.

With ACST-2 included, there is now as much evidence asymptomatic and symptomatic carotid stenosis—ITT analyses of non-procedural strokes (ipsilateral ischaemic stroke plus other strokes) plus other strokes)

Patients and doctors who take part in trials may well be atypical in various ways, so the absolute procedural hazards for typical patients treated by typical doctors may be better assessed by considering thoughtfully the evidence from large, recent, representative registries or routine health-care databases rather than by considering just the evidence from randomised trials. In the national German registry, asymptomatic patients undergoing CAS or CEA during 2014–19 had in both cases an in-hospital risk of disabling stroke or death of 0·7%, with median time to discharge of 4–5 days15 (appendix p 9). A risk of 0·7% within 4–5 days suggests a 30-day risk of disabling stroke or death of about 1% for each procedure, which is similar to that in ACST-2. Both in the German registry data and in ACST-2, CAS was associated with a slightly greater risk than CEA of non-disabling stroke.

Treatment was equally prompt in both study arms, so procedural endpoints could be defined as those within 30 days of the procedure (rather than within a fixed time since randomisation, as in some previous trials). The chief emphasis was on stroke, particularly disabling stroke, as procedural myocardial infarction was much less common than expected in the protocol, but there was no evidence that myocardial infarction had been underestimated. Cranial nerve damage following CEA was monitored only at 1 month, as it is usually either transient or not substantially disabling.19

Long-term follow-up sought only symptomatic strokes and did not image patients without symptoms. Follow-up thus far is to a mean of only 5 years, and properly informed medical decisions and reliable health economic evaluations could require even longer follow-up. If the disabling or fatal procedural hazards of CAS and CEA are similar, even moderate differences in long-term efficacy against stroke could be medically important. Analyses of registries or routine health-care databases cannot reliably assess moderate differences in long-term stroke rates, as there may well be systematic differences between the types of patients who undergo CAS and CEA that cannot be sufficiently controlled by mathematical modelling or propensity matching. Large-scale randomised evidence is necessary,4 and the present trial has more than doubled the number of asymptomatic patients in trials of CAS versus CEA.12–14 However, the randomised evidence from both asymptomatic and symptomatic patients is relevant.14–18 This is summarised in figure 4, the main aim of which is to see whether the results among the two types of patient can help reinforce each other, rather than to seek differences between them.

With ACST-2 included, there is now as much evidence asymptomatic and symptomatic carotid stenosis—ITT analyses of non-procedural strokes (ipsilateral ischaemic stroke plus other strokes) plus other strokes)
CEA are similar for at least the first few years. Further follow-up of ACST-2 and other trials will provide additional evidence on the durability of their protective effects.

Contributors
AH, RP, HP, and RB designed or executed this study and participated in the final analyses. This report was drafted by AH, RP, RB, and HP, and all authors revised it.

Declaration of interests
We declare no competing interests.

Data sharing
Follow-up of deaths and strokes will continue until 2026, when the final results will be reported and the dataset shared under Nuffield Department of Population Health (NDPH) data access policies.

Acknowledgments
The chief acknowledgments are to the patients who agreed to participate, and the collaborating doctors and trial staff listed in the appendix (pp 3–8). ACST-2 is currently funded from the core support from the Medical Research Council (MRC), the British Heart Foundation, and Cancer Research UK for the University of Oxford’s NDPH, and received grants from the BUPA Foundation (BUPAF/33a/05) and National Cancer Research UK for the University of Oxford’s NDPH, and received Medical Research Council (MRC), the British Heart Foundation, and National Institute for Health Research UK funding.

References
1. Cole TS, Mezher AW, Catapano JS, et al. Nationwide trends in carotid endarterectomy and carotid artery stenting in the post- CREST era. Stroke 2020; 51: 579–87.
2. Venermo M, Wang G, Sedarayyan A, et al. Editor’s choice—carotid stenosis treatment: variation in international practice patterns. Eur J Vasc Endovasc Surg 2017; 53: 511–19.
3. Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTiG). Karotis-Revaskularisation. https://iqtig.org/gps-verfahren/karotis/ (accessed July 22, 2021).
4. Halliday A, Harrison M, Hayter E, et al. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet 2010; 376: 1074–84.
5. Halliday A, Petor R, Bullnola R, et al. Carotid artery surgery to reduce long-term stroke rates: individual patient data meta-analysis of the randomised trials in asymptomatic patients. SSRN 2021; published online Aug 23. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3909921 (preprint).
6. Schmid S, Tsantilas P, Knappich C, et al. Risk of in-hospital stroke or death is associated with age but not sex in patients treated with carotid endarterectomy for asymptomatic or symptomatic stenosis in routine practice: secondary data analysis of the nationwide German statutory quality assurance database from 2009 to 2014. J Am Heart Assoc 2017; 6: e004764.
7. Collins R, Bowman L, Landray M, Petor R. The magic of randomisation and the myth of real-world evidence. N Engl J Med 2020; 382: 674–78.
8. Muller MD, Lyper P, Brown MM, Bonati LH. Carotid artery stenting versus endarterectomy for treatment of carotid artery stenosis. Cochrane Database Syst Rev 2020; 2: CD000515.
9. Chambers BR, Donnan G. Carotid endarterectomy for asymptomatic carotid stenosis. Cochrane Database Syst Rev 2005; 4: CD001923.
10. Hills RK, Gray R, Wheatey K. Balancing treatment allocations by clinician or center in randomized trials allows unacceptable levels of treatment prediction. J Evid Based Med 2009; 2: 196–204.
11. Zannetti S, Parente B, De Rango P, et al. Role of surgical techniques and operative findings in cranial and cervical nerve injuries during carotid endarterectomy. Eur J Vasc Endovasc Surg 1998; 15: 528–31.
12. Rosenfield K, Matsunuma JS, Chaturvedi S, et al. Randomized trial of stent versus surgery for asymptomatic carotid stenosis. N Engl J Med 2016; 374: 1011–20.
13. Reiff T, Eckstein HH, Mansmann U, et al. Angioplasty in asymptomatic carotid artery stenosis vs. endarterectomy compared to best medical treatment: one-year interim results of SPACE-2. Int J Stroke 2019; 15: 1747493019833017.
14. Brott TG, Howard G, Roubin GS, et al. Long-term results of stenting versus endarterectomy for carotid-artery stenosis. N Engl J Med 2016; 374: 1021–31.
15. Brott TG, Calvet D, Howard G, et al. Long-term outcomes of stenting and endarterectomy for symptomatic carotid stenosis: a preplanned pooled analysis of individual patient data. Lancet Neurol 2019; 18: 348–56.
16. Eckstein HH, Ringleb P, Allenberg JR, et al. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol 2008; 7: 893–902.
17. Bonati LH, Dobson J, Featherstone RL, et al. Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial. Lancet 2015; 385: 529–38.
18. Mas JL, Trinquart L, Leys D, et al. Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. Lancet Neurol 2008; 7: 885–92.